News | Prostate Cancer | March 27, 2018

Study finds metastatic cancer rates and cancer mortality rates drop significantly when brachytherapy combined with external beam radiation therapy

Combination Radiotherapy Beneficial in Treating Prostate Cancer

March 27, 2018 — While there are many treatment options for men with prostate cancer, a recent national study published in the Journal of the American Medical Association compared the effectiveness of treatments for high-risk prostate cancer.

Said Daniel Krauss, M.D., radiation oncologist and principal investigator at the Beaumont, Royal Oak research site, “Though retrospective, more than 1,800 very high-risk patients were relatively equally divided into treatment groups – primary surgery; external beam radiotherapy; and external beam with internal radiation (brachytherapy). Compared to other approaches, the combination of external beam and brachytherapy showed dramatic improvements in cancer mortality and metastatic disease rates – something radiation oncologists at Beaumont have suspected for some time.”

Researchers found treating patients with a combination of external beam with brachytherapy resulted in a decline in metastatic cancer rates from 25 to 8 percent. Metastatic cancer is cancer that has spread to a body site remote from where it started. Cancer mortality rates decreased from 12 percent in patients treated with primary surgery or external radiation alone, to 3 percent in patients treated with the combination of external radiation plus brachytherapy.

Brachytherapy is a form of radiation therapy that involves placing a radioactive source within the patient’s body at the site of the cancer. The radioactive source used to destroy the cancer is delivered by devices called implants.

Brachytherapy may be performed in combination with external beam radiation therapy to help destroy the main mass of tumor cells for certain types of cancer.

Krauss is a leading expert in treating prostate cancer with high-dose-rate brachytherapy. Depending on the type of prostate cancer, some patients can be treated entirely with two, or sometimes as little as one, minimally invasive brachytherapy treatment. He continues his research to further refine the treatment duration and establish an optimal treatment dose.

For more information: www.jamanetwork.com

Reference

Kishan A.U., Cook R.R., Ciezki J.P., et al. "Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer." Journal of the American Medical Association, March 6, 2018. doi:10.1001/jama.2018.0587

 


Related Content

News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
Subscribe Now